Overview

A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Lidocaine